Skin News and Research

RSS

Brain stimulation with ultrasound may enhance cognitive function

The ability to diagnose and treat brain dysfunction without surgery, may rely on a new method of noninvasive brain stimulation using pulsed ultrasound developed by a team of scientists led by William "Jamie" Tyler, a neuroscientist at Arizona State University. The approach, published in the journal Neuron on June 9, shows that pulsed ultrasound not only stimulates action potentials in intact motor cortex in mice but it also "elicits motor responses comparable to those only previously achieved with implanted electrodes and related techniques," says Yusuf Tufail, the lead author from ASU's School of Life Sciences.

10 Jun 2010

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Childhood cancer survivors diagnosed later with non-melanoma skin cancer may be at increased risk for having a malignant tumor within 15 years, according to research led by St. Jude Children's Research Hospital investigators.

10 Jun 2010

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

Researchers at Mount Sinai School of Medicine have for the first time differentiated human stem cells to become heart cells with cardiomyopathy, a condition in which the heart muscle cells are abnormal. The discovery will allow scientists to learn how those heart cells become diseased and from there, they can begin developing drug therapies to stop the disease from occurring or progressing. The study is published in the June 9th issue of Nature.

10 Jun 2010

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approval for its SPR-based HPV-DNA chip from the State Food and Drug Administration of China (the "SFDA").

10 Jun 2010

Home Run Challenge: PCF, MLB and MLBPA partner to raise funds for prostate cancer research

Major League Baseball players are putting their bats to work once again to help strike out prostate cancer as part of the Prostate Cancer Foundation's 14th Annual Home Run Challenge. The Home Run Challenge, a partnership between the Prostate Cancer Foundation, Major League Baseball and the Major League Baseball Players Association, begins today and runs through Father's Day, June 20, 2010.

9 Jun 2010

Surgery through eyelids avoid major head trauma

Surgeons at Johns Hopkins have safely and effectively operated inside the brains of a dozen patients by making a small entry incision through the natural creases of an eyelid to reach the skull and deep brain.

9 Jun 2010

ISSCR launches web site on stem cell treatments

The International Society for Stem Cell Research (ISSCR) announced today that it has launched "A Closer Look at Stem Cell Treatments" (www.closerlookatstemcells.org), a Web site to arm patients, their families and doctors with information they need to make decisions about stem cell treatments.

9 Jun 2010

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.

9 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Helix BioPharma Corp. today announced results from the Phase II clinical trial assessing the efficacy and safety of Topical Interferon Alpha-2b cream for the treatment of ano-genital warts (AGW).

9 Jun 2010

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

The Melanoma Network of Canada is excited with the new hope that long-anticipated results of a late-stage skin cancer trial brings to patients with advanced melanoma. The results, presented at the American Society of Clinical Oncology annual meeting, show increased survival with the experimental treatment ipilimumab in patients with previously-treated metastatic melanoma, the most deadly form of skin cancer.

9 Jun 2010

SciMed Technologies receives certification for VitaKit A from AOAC International

SciMed Technologies Inc. today announces they received certification from the AOAC International - a worldwide scientific association dedicated to analytical excellence - for VitaKit A the world's first 2 hour rapid test for accurate analysis of vitamin A in liquid milk.

8 Jun 2010

Vitiligo associated with genes variations linked to body's immune response

Scientists including researchers from the University of Florida have discovered additional evidence that generalized vitiligo - a disease that typically causes patches of white skin on the face, neck and extremities that pop star Michael Jackson may have experienced - is associated with slight variations in genes that play a role in the body's natural defenses.

8 Jun 2010

New study assesses accuracy of indirect estimated radiation doses during eTAAA

A new study, presented at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery® today, assessed the accuracy of indirect estimated radiation doses of 47 patients during endovascular thoracoabdominal aneurysm repair (eTAAA).

8 Jun 2010

TMI announces development of new clinical imaging system

With the results of the clinical trial at Duke University Medical Center completed, and the pending publication of the results, TMI is pleased to announce the development of their new clinical imaging system.

8 Jun 2010

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.

8 Jun 2010

Researchers decipher how mast cells set immune defense on right track

In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.

8 Jun 2010

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Threshold Pharmaceuticals, Inc. today announced results from Phase 1/2 clinical trials in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented during the American Society for Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.

8 Jun 2010

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Melinda Gates today urged global leaders to make women's and children's health a top priority, and announced that the Gates Foundation will invest $1.5 billion over the next five years to support maternal and child health, family planning, and nutrition programs in developing countries.

8 Jun 2010

Skin News and Research

Brain stimulation with ultrasound may enhance cognitive function

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

Home Run Challenge: PCF, MLB and MLBPA partner to raise funds for prostate cancer research

Surgery through eyelids avoid major head trauma

ISSCR launches web site on stem cell treatments

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

SciMed Technologies receives certification for VitaKit A from AOAC International

Vitiligo associated with genes variations linked to body's immune response

New study assesses accuracy of indirect estimated radiation doses during eTAAA

TMI announces development of new clinical imaging system

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Researchers decipher how mast cells set immune defense on right track

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News